Business
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
SAN CARLOS, Calif., June 26, 2025--In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today’s investor R&D Day. The event comes at a pivotal moment for the Company, which has more than 40 clinical and commercial stage assets in development, a signal of both scale and ambition.
About this update from Beone Medicines Ltd. Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":28492,"height":5743,"url":"https://media.zenfs.com/en/business-wire.com/ee9beb0256c65b95fc60379536e8f641"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OuevpUQf20bB0155UVq35Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ee9beb0256c65b95fc60379536e8f641","width":960,"height":194},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/FveJFsntIBjgMk6ptAJzSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ee9beb0256c65b95fc60379536e8f641","width":1200,"height":242}},"lazy":false},{"type":"text","content":"BRUKINSA, sonrotoclax, and BTK CDAC data, including combinations, are designed to comprehensively address unmet needs across CLL patient populations","length":148,"tagName":"p","attribs":{}},{"type":"text","content":"Promising new data from pipeline assets in breast, lung, and GI cancer franchises, including CDK4 inhibitor, B7-H4 ADC, and novel PRMT5 inhibitor, will be featured","length":163,"tagName":"p","attribs":{}},{"type":"text","content":"Pipeline is at an exciting inflection point with 20 near-term milestones in the next 18 months","length":94,"tagName":"p","attribs":{}},{"type":"text","content":"SAN CARLOS, Calif., June 26, 2025--(BUSINESS WIRE)--In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today’s investor R&D Day. The event comes at a pivotal moment for the Company, which has more than 40 clinical and commercial stage assets in development, a signal of both scale and ambition.","length":459,"tagName":"p"},{"type":"text","content":""At BeOne, our mission is simple yet bold: to create the world’s first next-generation oncology company," said John V. Oyler, Co-Founder, Chairman, and CEO. "What we will unveil demonstrates our progress towards this goal today, and the promise for tomorrow. From our innovative discovery engine to one of the broadest pipelines in oncology, we are well-positioned to bring transformative medicines to patients worldwide—and to do so with speed, quality, and purpose."","length"...